



Communiqué de Presse

Paris, July 4th 2013

Kurma Life Sciences Partners and Idinvest Partners announce the success of IPO of Prosensa Holding B.V

On Friday June 28th, Prosensa Holding B.V. (Prosensa) initiated its first trading day on the Nasdaq New York, US. Prosensa is the second Idinvest Biotech portfolio company completing a market listing this year. Earlier in 2013, Erytech Pharma, a French company specialized in innovative therapeutic approach for rare cancers was admitted on NYSE Euronext Paris.

Prosensa is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease.

Prosensa announced On Thursday June 27th, the pricing of its initial public offering of 6,000,000 of its ordinary shares at an initial public offering price of \$13.00 per share corresponding to a \$455M company market cap, before underwriting discounts. Prosensa has also granted the underwriters a 30-day option to purchase up to an additional 900,000 ordinary shares to cover over-allotments, if any.

On the 28th of June, after the first trading day, Prosensa's shares were up 48,08% above its initial public offering price of \$13 at \$19.25 (+\$6,25/share) providing a \$674M market cap to the company.

In September 2010 KLS Partners and IDInvest Partners entered into an agreement under which Kurma manages the biotechnology portfolio of IdInvest, of 87 million Euros total investments. Within this contract KLS Partners has responsibility for the Idinvest investment in Prosensa Holding B.V.



About KLS Partners - www.kls-partners.com

Founded in July 2009, KLS Partners is a key European player in venture capital, development capital and technology transfer in the field of life sciences (biotechnologies, health, nutrition, environmental sciences), notably through the Kurma Biofund venture capital fund and strategic partnerships with forefront European biotechnology medical research centers.

About Idinvest Partners - www.idinvest.com

With €4 billion under management and 40 staff, Idinvest Partners is a leading pan-European manager focused on the middle market segment. Idinvest Partners has developed several complementary areas of expertise including investments in innovative European start-ups, primary, secondary and mezzanine investments in European non-listed companies, and private equity consulting. Founded under the name AGF Private Equity in 1997, Idinvest Partners was formerly part of the Allianz Group until 2010 when it joined forces with IDI Group to become independent.

Press contact

NewCap. - Nicolas Merigeau : +33(0)1 44 51 94 98 - nmerigeau@newcap.fr